Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    Agkistrodon piscivorus antivenin

    go.drugbank.com/drugs/DB13894
    Approved

    The cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae). … Approximately 99% of all venomous snake bites in the United States are caused by Crotalidae, also known as _pit vipers_.

  2. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  3. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  4. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

    Synonyms: 3,4-Methylenedioxy-N-isopropylamphetamine
  5. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  6. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  7. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  8. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.

  9. Drug

    AVI-4557

    go.drugbank.com/drugs/DB05447
    Experimental

    in clearance and an increase in maximal blood concentration (Cmax). … AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently

  10. Drug

    INGN 225

    go.drugbank.com/drugs/DB05325
    Investigational

    INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.